Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00224016 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
A Phase 4 study of Detrusor Hyperreflexia, sponsored by Watson Pharmaceuticals.
- Completed
- Registry status
- Phase 4
- Development phase
- 57
- Enrollment target
- 20
- Study locations
NCT00224016 is a Phase 4 study of Detrusor Hyperreflexia that has completed, run by Watson Pharmaceuticals. The registered enrollment target is 57 participants. The trial reports 20 study locations across 15 states.
The verdict
NCT00224016, a Phase 4 study of Detrusor Hyperreflexia, has completed, sponsored by Watson Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 57 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder.
Conditions Studied
Interventions
- DRUG Oxybutynin
Study Locations (20)
New York
- Watson Investigational Site - Albany
- Watson Investigational Site - Buffalo
- Watson Investigational Site - Poughkeepsie
California
- Watson Investigational Site - Orange County
- Watson Investigational Site - San Diego
Missouri
- Watson Investigational Site - Kansas City
- Watson Investigational Site - St Louis
North Carolina
- Watson Investigational Site - Ashville
- Watson Investigational Site - Durham
Arkansas
- Watson Investigational Site - Little Rock
Colorado
- Watson Investigational Site - Denver
District of Columbia
- Watson Investigational Site - Washington D.C.
Michigan
- Watson Investigational Site - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2004-12 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00224016
The ClinicalTrials.gov registry entry for NCT00224016 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Watson Pharmaceuticals, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Detrusor Hyperreflexia appearing as the primary indexed condition, and to 1 intervention - of which Oxybutynin is the first listed.
NCT00224016 reports 20 study locations spanning 15 distinct geographic areas - top geographies include New York, California, Missouri.
Frequently Asked Questions
What is clinical trial NCT00224016 about?
NCT00224016 is a clinical study titled "Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition". This study will evaluate the safety and effectiveness of an anticholinergic drug treatment administered by transdermal patch to treat overactive bladder in children who have a neurological condition (e.g. spina bifida) that contributes to their overactive bladder.
What is the current status of trial NCT00224016?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 57 participants. The study started on 2004-12. Estimated completion is 2008-09.
What conditions does trial NCT00224016 study?
This clinical trial studies the following conditions: Detrusor Hyperreflexia.
What interventions are being tested in trial NCT00224016?
The interventions under investigation include: Oxybutynin (DRUG).
Who is sponsoring clinical trial NCT00224016?
This trial is sponsored by Watson Pharmaceuticals, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00224016 being conducted?
This trial has 20 study locations across Arkansas, California, Colorado, District of Columbia, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Detrusor Hyperreflexia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.